Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy

Linda Mesler Muul, Elaine P. Director, Cornelia L. Hyatt, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Immunotherapy utilizing the adoptive transfer of lymphokine activated killer (LAK) cells in conjunction with recombinant interleukin 2 (RIL-2) is capable of reducing established metastatic cancer in a variety of animal tumor models. A major difficulty in the application of these efforts to the treatment of human cancer has been the activation in vitro of up to 2 × 1011 human peripheral blood lymphocytes obtained by repeated leukaphereses. We have thus developed optimal and simplified techniques for the generation of human LAK cells for use in clinical trials. We have found that 1.5 × 109 lymphocytes separated on Ficoll-Hypaque gradients and incubated in 1000 ml of culture medium in a 2.3 liter roller bottle with 1000-1500 U of RIL-2 per ml, generated LAK cells capable of killing fresh human tumor cells in a 4 h chromium release assay. The culture medium used was RPMI 1640 with 2 mM glutamine, 2% heat-inactivated human AB serum, 50 μg/ml streptomycin and gentamicin and 50 U/ml penicillin. This technique allows activation of sufficient numbers of cells in a research laboratory setting to conduct human clinical trials. The administration of LAK cells generated in this fashion can mediate the regression of human tumors when administered in conjunction with IL-2.

Original languageEnglish (US)
Pages (from-to)265-275
Number of pages11
JournalJournal of Immunological Methods
Volume88
Issue number2
DOIs
StatePublished - Apr 17 1986
Externally publishedYes

Fingerprint

Adoptive Immunotherapy
Lymphokine-Activated Killer Cells
Interleukin-2
Neoplasms
Culture Media
Clinical Trials
Lymphocytes
Diatrizoate
Leukapheresis
Ficoll
Adoptive Transfer
Streptomycin
Chromium
Gentamicins
Glutamine
Penicillins
Immunotherapy
Animal Models
Cell Count
Hot Temperature

Keywords

  • Adoptive immunotherapy
  • Human cytotoxic lymphocytes
  • Recombinant interleukin 2

ASJC Scopus subject areas

  • Biotechnology
  • Immunology

Cite this

Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. / Mesler Muul, Linda; Director, Elaine P.; Hyatt, Cornelia L.; Rosenberg, Steven A.

In: Journal of Immunological Methods, Vol. 88, No. 2, 17.04.1986, p. 265-275.

Research output: Contribution to journalArticle

Mesler Muul, Linda ; Director, Elaine P. ; Hyatt, Cornelia L. ; Rosenberg, Steven A. / Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. In: Journal of Immunological Methods. 1986 ; Vol. 88, No. 2. pp. 265-275.
@article{6729ac245a3b4d19ab47ceec7de68439,
title = "Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy",
abstract = "Immunotherapy utilizing the adoptive transfer of lymphokine activated killer (LAK) cells in conjunction with recombinant interleukin 2 (RIL-2) is capable of reducing established metastatic cancer in a variety of animal tumor models. A major difficulty in the application of these efforts to the treatment of human cancer has been the activation in vitro of up to 2 × 1011 human peripheral blood lymphocytes obtained by repeated leukaphereses. We have thus developed optimal and simplified techniques for the generation of human LAK cells for use in clinical trials. We have found that 1.5 × 109 lymphocytes separated on Ficoll-Hypaque gradients and incubated in 1000 ml of culture medium in a 2.3 liter roller bottle with 1000-1500 U of RIL-2 per ml, generated LAK cells capable of killing fresh human tumor cells in a 4 h chromium release assay. The culture medium used was RPMI 1640 with 2 mM glutamine, 2{\%} heat-inactivated human AB serum, 50 μg/ml streptomycin and gentamicin and 50 U/ml penicillin. This technique allows activation of sufficient numbers of cells in a research laboratory setting to conduct human clinical trials. The administration of LAK cells generated in this fashion can mediate the regression of human tumors when administered in conjunction with IL-2.",
keywords = "Adoptive immunotherapy, Human cytotoxic lymphocytes, Recombinant interleukin 2",
author = "{Mesler Muul}, Linda and Director, {Elaine P.} and Hyatt, {Cornelia L.} and Rosenberg, {Steven A.}",
year = "1986",
month = "4",
day = "17",
doi = "10.1016/0022-1759(86)90015-3",
language = "English (US)",
volume = "88",
pages = "265--275",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy

AU - Mesler Muul, Linda

AU - Director, Elaine P.

AU - Hyatt, Cornelia L.

AU - Rosenberg, Steven A.

PY - 1986/4/17

Y1 - 1986/4/17

N2 - Immunotherapy utilizing the adoptive transfer of lymphokine activated killer (LAK) cells in conjunction with recombinant interleukin 2 (RIL-2) is capable of reducing established metastatic cancer in a variety of animal tumor models. A major difficulty in the application of these efforts to the treatment of human cancer has been the activation in vitro of up to 2 × 1011 human peripheral blood lymphocytes obtained by repeated leukaphereses. We have thus developed optimal and simplified techniques for the generation of human LAK cells for use in clinical trials. We have found that 1.5 × 109 lymphocytes separated on Ficoll-Hypaque gradients and incubated in 1000 ml of culture medium in a 2.3 liter roller bottle with 1000-1500 U of RIL-2 per ml, generated LAK cells capable of killing fresh human tumor cells in a 4 h chromium release assay. The culture medium used was RPMI 1640 with 2 mM glutamine, 2% heat-inactivated human AB serum, 50 μg/ml streptomycin and gentamicin and 50 U/ml penicillin. This technique allows activation of sufficient numbers of cells in a research laboratory setting to conduct human clinical trials. The administration of LAK cells generated in this fashion can mediate the regression of human tumors when administered in conjunction with IL-2.

AB - Immunotherapy utilizing the adoptive transfer of lymphokine activated killer (LAK) cells in conjunction with recombinant interleukin 2 (RIL-2) is capable of reducing established metastatic cancer in a variety of animal tumor models. A major difficulty in the application of these efforts to the treatment of human cancer has been the activation in vitro of up to 2 × 1011 human peripheral blood lymphocytes obtained by repeated leukaphereses. We have thus developed optimal and simplified techniques for the generation of human LAK cells for use in clinical trials. We have found that 1.5 × 109 lymphocytes separated on Ficoll-Hypaque gradients and incubated in 1000 ml of culture medium in a 2.3 liter roller bottle with 1000-1500 U of RIL-2 per ml, generated LAK cells capable of killing fresh human tumor cells in a 4 h chromium release assay. The culture medium used was RPMI 1640 with 2 mM glutamine, 2% heat-inactivated human AB serum, 50 μg/ml streptomycin and gentamicin and 50 U/ml penicillin. This technique allows activation of sufficient numbers of cells in a research laboratory setting to conduct human clinical trials. The administration of LAK cells generated in this fashion can mediate the regression of human tumors when administered in conjunction with IL-2.

KW - Adoptive immunotherapy

KW - Human cytotoxic lymphocytes

KW - Recombinant interleukin 2

UR - http://www.scopus.com/inward/record.url?scp=0022654504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022654504&partnerID=8YFLogxK

U2 - 10.1016/0022-1759(86)90015-3

DO - 10.1016/0022-1759(86)90015-3

M3 - Article

C2 - 3485692

AN - SCOPUS:0022654504

VL - 88

SP - 265

EP - 275

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 2

ER -